Ironwood Pharmaceuticals Inc expected to post earnings of 19 cents a share - Earnings Preview

Ironwood Pharmaceuticals

07/05/2024 15:31

* Ironwood Pharmaceuticals Inc  IRWD.OQ   IRWD.O  is
expected
to show a rise in quarterly revenue when it reports  results on
May 9 for the period ending March 31 2024
    * The Boston Massachusetts-based  company is expected to
report a
1.7% increase in revenue to $105.804 million from $104.06
million a year ago, according to the mean estimate from 6
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Ironwood Pharmaceuticals
Inc
is for earnings of 19 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Ironwood
Pharmaceuticals Inc is $17.50​, above​ its last closing price
of $8.11. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.21        0.21       -0.01     Missed  -104.9
 Sep. 30 2023  0.17        0.16       0.09      Missed  -42.9
 Jun. 30 2023  0.26        0.25       0.31      Beat    25.7​
 Mar. 31 2023  0.23        0.24       0.25      Beat    3.1
 ​​Dec.        0.26        0.27       0.27      Met     0
 31 2022                                                
 Jan. 1 0001   0.26        0.27       0.28      Beat    5.7​
 Jan. 1 0001   0.30        0.30       0.21      Missed  -28.8
 Mar. 31 2022  0.25        0.26       0.21      Missed  -17.6
 This summary was machine generated May 7 at 14:31 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)